Refine
Has Fulltext
- yes (43) (remove)
Is part of the Bibliography
- yes (43)
Year of publication
Document Type
- Journal article (43)
Language
- English (43)
Keywords
- gene expression (5)
- melanoma (4)
- Biologie (3)
- Medizin (3)
- prostate cancer (3)
- NRF2 (2)
- RCC (2)
- T cells (2)
- biomarker (2)
- evolutionary genetics (2)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (35)
- Urologische Klinik und Poliklinik (8)
- Pathologisches Institut (6)
- Comprehensive Cancer Center Mainfranken (5)
- Institut für Virologie und Immunbiologie (3)
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (3)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (3)
- Medizinische Klinik und Poliklinik II (3)
- Rudolf-Virchow-Zentrum (3)
- Julius-von-Sachs-Institut für Biowissenschaften (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Augenklinik und Poliklinik (1)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Frauenklinik und Poliklinik (1)
- Institut für Experimentelle Biomedizin (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Institut für Physikalische und Theoretische Chemie (1)
- Klinik und Poliklinik für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie (1)
- Klinik und Poliklinik für Nuklearmedizin (1)
- Klinik und Poliklinik für Strahlentherapie (1)
- Lehrstuhl für Biochemie (1)
- Lehrstuhl für Molekulare Psychiatrie (1)
- Lehrstuhl für Tissue Engineering und Regenerative Medizin (1)
- Neurologische Klinik und Poliklinik (1)
- Physiologisches Institut (1)
Sonstige beteiligte Institutionen
- IZKF (Interdisziplinäres Zentrum für Klinische Forschung), Universität Würzburg (1)
- IZKF Laboratory for Microarray Applications, University Hospital of Wuerzburg, Wuerzburg, Germany (1)
- Microarray Core Unit, Interdisciplinary Center for Clinical Science, University of Würzburg, Versbacher Straße, Würzburg 97080, Germany (1)
Downregulation of miR-221-3p expression in prostate cancer (PCa) predicted overall and cancer-specific survival of high-risk PCa patients. Apart from PCa, miR-221-3p expression levels predicted a response to tyrosine kinase inhibitors (TKI) in clear cell renal cell carcinoma (ccRCC) patients. Since this role of miR-221-3p was explained with a specific targeting of VEGFR2, we examined whether miR-221-3p regulated VEGFR2 in PCa. First, we confirmed VEGFR2/KDR as a target gene of miR-221-3p in PCa cells by applying Luciferase reporter assays and Western blotting experiments. Although VEGFR2 was mainly downregulated in the PCa cohort of the TCGA (The Cancer Genome Atlas) database, VEGFR2 was upregulated in our high-risk PCa cohort (n = 142) and predicted clinical progression. In vitro miR-221-3p acted as an escape mechanism from TKI in PC3 cells, as displayed by proliferation and apoptosis assays. Moreover, we confirmed that Sunitinib induced an interferon-related gene signature in PC3 cells by analyzing external microarray data and by demonstrating a significant upregulation of miR-221-3p/miR-222-3p after Sunitinib exposure. Our findings bear a clinical perspective for high-risk PCa patients with low miR-221-3p levels since this could predict a favorable TKI response. Apart from this therapeutic niche, we identified a partially oncogenic function of miR-221-3p as an escape mechanism from VEGFR2 inhibition.